Stereotactic radiosurgery eligibility and selection bias in the treatment of glioblastoma multiforme.
Several single institution studies have shown a survival advantage when a stereotactic radiosurgery (SRS) boost followed fractionated external beam radiation (FracRT) in the treatment of glioblastoma (GBM). RTOG 93-05 employed SRS before FracRT and demonstrated no survival benefit. We examined the effect of SRS eligibility before and after FracRT on patient outcome in a group of patients treated with conventional therapy without SRS. From 1998 to 2008, 106 patients with GBM treated definitively at the University of Utah were divided into groups based on eligibility for SRS: ineligible ("Never"), eligible before FracRT ("All Pre"), eligible before FracRT only ("Pre Only"), or eligible before and after FracRT ("Always"). Overall (OS) and progression-free survival (PFS) based on SRS eligibility was assessed. Eleven patients were alive at the time of analysis with a median follow-up of 42.3 months. Median OS for groups "All Pre" (n = 29), "Always" (n = 17), "Pre Only" (n = 12), and "Never" (n = 77) were 13.6, 13.6, 12.4, and 9.2 months, respectively. Of the 29 patients in group "All Pre," 12 (41.4%) were ineligible for SRS following FracRT. PFS did not significantly differ between groups. SRS for GBM can only be of benefit to selected patients with minimal focal postoperative disease. Following FracRT, over a third of initially SRS-eligible patients demonstrated more extensive disease in our experience. It is possible inclusion of such patients in a series of SRS for GBM could mask a benefit in remaining patients. No significant difference in OS or PFS based on SRS-eligibility status was found.
Anker
Christopher J
CJ
Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah School of Medicine, 1950 Circle of Hope, Rm. 1570, Salt Lake City, UT, 581-2396, USA. chris.anker@hci.utah.edu
Hymas
Richard V
RV
Hazard
Lisa J
LJ
Boucher
Kenneth M
KM
Jensen
Randy L
RL
Shrieve
Dennis C
DC
D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D005260:Female; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000601:surgery*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D016634:Radiosurgery / Q000379:methods*; D012189:Retrospective Studies; D015983:Selection Bias; D013997:Time Factors
J Natl Cancer Inst. 1993 May 5;85(9):704-10
8478956
Can J Neurol Sci. 1997 May;24(2):110-5
9164686
Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31
231022
Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):461-8
7673034
Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):842-54
12377338
Cancer Res. 2002 Mar 15;62(6):1915-9
11912174
Can J Neurol Sci. 1997 Nov;24(4):307-12
9398977
J Neurosurg. 1978 Sep;49(3):333-43
355604
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
Oncology (Williston Park). 1990 Mar;4(3):21-31; discussion 32, 37, 41
2168729
Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):144-50
17306935
N Engl J Med. 1980 Dec 4;303(23):1323-9
7001230
Acta Radiol. 1989 May-Jun;30(3):225-32
2660886
Br J Cancer. 1991 Oct;64(4):769-74
1654987
Int J Radiat Oncol Biol Phys. 1999 Jan 1;43(1):79-88
9989517
Int J Radiat Oncol Biol Phys. 1992;24(1):55-7
1512163
Neurosurgery. 2002 Jan;50(1):41-6; discussion 46-7
11844233
Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1405-9
2542195
J Clin Oncol. 1993 May;11(5):857-62
8487050
Radiother Oncol. 1991 Feb;20(2):99-110
1851573
Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):517-26
10802381
Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):931-41
7607967
J Clin Oncol. 1990 Jul;8(7):1277-80
2358840
Int J Radiat Oncol Biol Phys. 1991 Aug;21(3):601-6
1651302
Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):614-5; author reply 615-6
15890607
Radiology. 1993 Jan;186(1):45-53
8380108
Neuro Oncol. 2008 Jun;10(3):361-7
18401015
Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):71-7
11163499
Cancer Res. 2001 Mar 15;61(6):2744-50
11289157
Lancet Oncol. 2009 May;10(5):459-66
19269895
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):511-9
16168843
J Clin Oncol. 2002 Mar 15;20(6):1635-42
11896114
J Neurosurg. 1999 Jan;90(1):72-7
10413158
J Natl Cancer Inst. 1990 Dec 19;82(24):1918-21
2250312
J Neurooncol. 2002 Apr;57(2):151-60
12125977
J Clin Oncol. 1992 Sep;10(9):1379-85
1325539
Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1005-11
9719109
Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1351-8
11121633
Am J Clin Oncol. 2004 Oct;27(5):516-21
15596923
Neurosurgery. 2002 Aug;51(2):343-55; discussion 355-7
12182772
AJNR Am J Neuroradiol. 1985 Jul-Aug;6(4):505-14
2992257
Neurosurgery. 1997 Oct;41(4):776-83; discussion 783-5
9316038
Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1045-53
8985026
Int J Radiat Oncol Biol Phys. 1994 Oct 15;30(3):541-9
7928484
Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):853-60
15465203